191 related articles for article (PubMed ID: 33524545)
1. Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.
Roy S; Grimes S; Morgan SC; Eapen L; Malone J; Craig J; Spratt DE; Malone S
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1101-1113. PubMed ID: 33524545
[TBL] [Abstract][Full Text] [Related]
2. Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial.
Roy S; Spratt DE; Morgan SC; Zhou M; D'Souza LA; Drogos F; Malone J; Grimes S; Gualano C; MacRae R; Mukherjee D; Malone S
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):880-889. PubMed ID: 34788698
[TBL] [Abstract][Full Text] [Related]
3. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
Spratt DE; Malone S; Roy S; Grimes S; Eapen L; Morgan SC; Malone J; Craig J; Dess RT; Jackson WC; Hartman HE; Kishan AU; Mehra R; Kaffenberger S; Morgan TM; Reichert ZR; Alumkal JJ; Michalski J; Lee WR; Pisansky TM; Feng FY; Shipley W; Sandler HM; Schipper MJ; Roach M; Sun Y; Lawton CAF
J Clin Oncol; 2021 Jan; 39(2):136-144. PubMed ID: 33275486
[TBL] [Abstract][Full Text] [Related]
4. Impact of Sequencing of Androgen Suppression and Radiation Therapy on Testosterone Recovery in Localized Prostate Cancer.
Roy S; Grimes S; Eapen L; Spratt DE; Malone J; Craig J; Morgan SC; Malone S
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1179-1188. PubMed ID: 32565318
[TBL] [Abstract][Full Text] [Related]
5. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
6. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
7. Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.
Malone S; Roy S; Eapen L; E C; MacRae R; Perry G; Bowen J; Samant R; Morgan S; Craig J; Malone K; Grimes S
J Clin Oncol; 2020 Feb; 38(6):593-601. PubMed ID: 31829912
[TBL] [Abstract][Full Text] [Related]
8. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma TM; Sun Y; Malone S; Roach M; Dearnaley D; Pisansky TM; Feng FY; Sandler HM; Efstathiou JA; Syndikus I; Hall EC; Tree AC; Sydes MR; Cruickshank C; Roy S; Bolla M; Maingon P; De Reijke T; Nabid A; Carrier N; Souhami L; Zapatero A; Guerrero A; Alvarez A; Gonzalez San-Segundo C; Maldonado X; Romero T; Steinberg ML; Valle LF; Rettig MB; Nickols NG; Shoag JE; Reiter RE; Zaorsky NG; Jia AY; Garcia JA; Spratt DE; Kishan AU;
J Clin Oncol; 2023 Feb; 41(4):881-892. PubMed ID: 36269935
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal SA; Hunt D; Sartor AO; Pienta KJ; Gomella L; Grignon D; Rajan R; Kerlin KJ; Jones CU; Dobelbower M; Shipley WU; Zeitzer K; Hamstra DA; Donavanik V; Rotman M; Hartford AC; Michalski J; Seider M; Kim H; Kuban DA; Moughan J; Sandler H
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):294-302. PubMed ID: 26209502
[TBL] [Abstract][Full Text] [Related]
10. Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer.
Roy S; Morgan SC; Spratt DE; MacRae RM; Grimes S; Malone J; Mukherjee D; Malone S
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e61-e68. PubMed ID: 34728131
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
12. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
15. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
Lawton CA; DeSilvio M; Roach M; Uhl V; Kirsch R; Seider M; Rotman M; Jones C; Asbell S; Valicenti R; Hahn S; Thomas CR
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):646-55. PubMed ID: 17531401
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
19. Comparison of neoadjuvant vs concurrent/adjuvant androgen deprivation in men with high-risk prostate cancer receiving definitive radiation therapy.
Lee A; Becker DJ; Lederman AJ; Osborn VW; Shao MS; Wong AT; Schwartz D; Schreiber D
Tumori; 2017 Jul; 103(4):387-393. PubMed ID: 28085179
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S
Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
